Prevalence of testosterone deficiency in HIV-infected men under antiretroviral therapy

BMC Infectious Diseases

Volumn 16, Issue 1, 2016, Pages

  Gomes, Ana Rita ^a   Souteiro, Pedro ^b   Silva, Carolina Germana ^a   Sousa Pinto, Bernardo ^a   Almeida, Francisco ^a   Sarmento, António ^a   Carvalho, Davide ^a,b   Freitas, Paula ^a,b  

^a University of Porto   (Portugal)

^b Universidade do Porto   (Portugal)

Author keywords

Cardiovascular risk; HIV infection; Hypogonadism; Lipodystrophy

Indexed keywords

FOLLITROPIN; HEMOGLOBIN A1C; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INTEGRASE INHIBITOR; LUTEINIZING HORMONE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TESTOSTERONE; ANTIRETROVIRUS AGENT; GLYCATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; ANDROGEN DEFICIENCY; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; FRAMINGHAM RISK SCORE; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGONADOTROPISM; HYPOGONADOTROPIC HYPOGONADISM; LIPID STORAGE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PREVALENCE; SYSTOLIC BLOOD PRESSURE; BLOOD; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; HYPOGONADISM; METABOLISM; MIDDLE AGED; PORTUGAL; RISK FACTOR;

ADULT; ANTI-RETROVIRAL AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; FOLLICLE STIMULATING HORMONE; GLYCATED HEMOGLOBIN; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; HYPOGONADISM; LUTEINIZING HORMONE; MALE; METABOLIC SYNDROME; MIDDLE AGED; PORTUGAL; PREVALENCE; RISK FACTORS; TESTOSTERONE;

EID: 84993993803     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-016-1892-5     Document Type: Article

References (28)

1. Crum NF, Furtek KJ, Olson PE, Amling CL, Wallace MR. A review of hypogonadism and erectile dysfunction among HIV-infected men during the pre- and post-HAART eras: diagnosis, pathogenesis, and management. AIDS Patient Care STDS. 2005;19:655-71.
2. Unachukwu C, Uchenna D, Young E. Endocrine and metabolic disorders associated with human immune deficiency virus infection. West Afr J Med. 2009;28:3-9.
3. Sellmeyer DE, Grunfeld C. Endocrine and metabolic disturbances in human immunodeficiency virus infection and the acquired immune deficiency syndrome. Endocr Rev. 1996;17:518-32. The Endocrine Society.
4. Rochira V, Zirilli L, Orlando G, Santi D, Brigante G, Diazzi C, et al. Premature decline of serum total testosterone in HIV-infected men in the HAART-Era. PLoS One. 2011;6.
5. Bhasin S, Storer TW, Javanbakht M, Berman N, Yarasheski KE, Phillips J, et al. Testosterone Replacement and Resistance Exercise in HIV-Infected Men With Weight Loss and Low Testosterone Levels. JAMA. 2000;283:763-70.
6. Klein RS, Lo Y, Santoro N, Dobs AS. Androgen levels in older men who have or who are at risk of acquiring HIV infection. Clin Infect Dis. 2005;41:1794-803.
7. Ashby J, Goldmeier D, Sadeghi-Nejad H. Hypogonadism in human immunodeficiency virus-positive men. Korean J Urol. 2014;55:9-16.
8. Rochira V, Guaraldi G. Hypogonadism in the HIV-Infected Man. Endocrinol Metab Clin North Am. 2014;43:709-30. Elsevier Inc.
9. Crum-Cianflone NF, Bavaro M, Hale B, Amling C, Truett A, Brandt C, et al. Erectile dysfunction and hypogonadism among men with HIV. AIDS Patient Care STDS. 2007;21:9-19.
10. Castro KG, Ward JW, Slutsker L, Buehler JW, Jaffe HW, Berkelman RL, et al. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morb Mortal Wkly Report, Natl Cent Infect Dis Div HIV/AIDS, Centers Dis Control Prev. 1992;41:1-19.
11. Freitas P, Carvalho D, Santos AC, Mesquita J, Matos MJ, Madureira AJ, et al. Lipodystrophy defined by Fat Mass Ratio in HIV-infected patients is associated with a high prevalence of glucose disturbances and insulin resistance. BMC Infect Dis. 2012;12:180.
12. Freitas P, Carvalho D, Santos AC, Mesquita J, Correia F, Xerinda S, et al. Assessment of body fat composition disturbances by bioimpedance analysis in HIV-infected adults. J Endocrinol Invest. 2011;34:321-9.
13. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation. 2002;106:3143.
14. Vermeulen A, Verdonck L, Kaufman JM. A Critical Evaluation of Simple Methods for the Estimation of Free Testosterone in Serum. J Clin Endocrinol Metab. 1999;84:3666-72.
15. D'Agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care: The Framingham heart study. Circulation. 2008;117:743-53.
16. Grundy SM, Cleeman JI, Bairey Merz CN, Brewer HB, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-39.
17. Goff DC, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Gibbons R, et al. ACC/AHA guideline on the assessment of cardiovascular risk: A report of the American college of cardiology/American heart association task force on practice guidelines. Circulation. 2013;2014:129.
18. Cotter AG, Powderly WG. Endocrine complications of human immunodeficiency virus infection: Hypogonadism, bone disease and tenofovir-related toxicity. Best Pract Res Clin Endocrinol Metab. 2011;25:501-15. Elsevier Ltd.
19. Potenza M, Shimshi M. Male hypogonadism: The unrecognized cardiovascular risk factor. J Clin Lipidol. 2008;2:71-8.
20. Antonio L, Wu FCW, O'Neill TW, Pye SR, Ahern TB, Laurent MR, et al. Low Free Testosterone is Associated with Hypogonadal Signs and Symptoms in Men with Normal Total Testosterone. J Clin Endocrinol Metab. 2016;101(7):2647-57
21. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, et al. Testosterone therapy in Men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2010;95:2536-59. The Endocrine Society.
22. De Paepe ME, Vuletin JC, Lee MH, Rojas-Corona RR, Waxman M. Testicular atrophy in homosexual AIDS patients: An immune-mediated phenomenon? Hum Pathol Elsevier. 2016;20:572-8.
23. Wunder DM, Fux CA, Bersinger NA, Mueller NJ, Hirschel B, Cavassini M, et al. Androgen and gonadotropin patterns differ in HIV-1-infected men who develop lipoatrophy during antiretroviral therapy: A case-control study. HIV Med. 2008;9:427-32.
24. Bhasin S, Parker RA, Sattler F, Haubrich R, Alston B, Umbleja T, et al. Effects of testosterone supplementation on whole body and regional Fat mass and distribution in human immunodeficiency virus-infected Men with abdominal obesity. J Clin Endocrinol Metab. 2007;92:1049-57. The Endocrine Society.
25. Shahbaz S, Manicardi M, Guaraldi G, Raggi P. Cardiovascular disease in human immunodeficiency virus infected patients: A true or perceived risk? World J Cardiol. 2015;7:633-44.
26. Corona G, Rastrelli G, Monami M, Guay A, Buvat J, Sforza A, et al. Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. Eur J Endocrinol. 2011;165:687-701.
27. Regan S, Meigs JB, Massaro J, Agostino RBD, Grinspoon SK, Triant VA, et al. Evaluation of the ACC / AHA CVD Risk Prediction Algorithm Among HIV-Infected Patients Contact CROI Conf. 2009
28. Angela M. Thompson-Paul, Lichtenstein KA, Armon C, Buchacz K, Debes R, Chmiel JS, et al. Cardiovascular Disease Risk Prediction in the HIV Outpatient Study (HOPS). CROI Conf. 2015.